Shares of Dr Reddy’s Laboratories dropped 6.5 percent to 1,261 rupees on the BSE after the firm announced a delay in commercial supplies of its semaglutide product. The postponement stems from a quality issue involving the active pharmaceutical ingredient in specific batches. The company stated in a regulatory filing that certain lots failed specifications and that an investigation is underway to determine the cause. Corrective steps are being implemented to maintain standards. Commercial distribution will resume only after the matter is addressed. Officials confirmed the situation does not affect patient safety or existing regulatory submissions worldwide. The firm also noted its ongoing focus on consistent global availability of the therapy. A conference call is planned for further discussion. The announcement follows the recent Indian launch of an oral semaglutide tablet under the Obeda brand for type-2 diabetes treatment. The product comes in three strengths priced at 99, 135 and 225 rupees per tablet. The company had highlighted the introduction as part of efforts to expand its GLP-1 offerings after releasing a generic injectable version earlier. In its January-March results, consolidated net profit fell 86 percent year on year to 221 crore rupees while revenue declined 12 percent to 7,516 crore rupees. The earnings drop was linked mainly to lower Lenalidomide sales, pricing pressure in key markets and a one-time impact.
